You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

CLINICAL TRIALS PROFILE FOR FLUZOPARIB

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Fluzoparib

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02575651 ↗	A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies	Completed	307 Hospital of PLA	Phase 1	Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of Fluzoparib will be investigated.
NCT02575651 ↗	A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies	Completed	Beijing Cancer Hospital	Phase 1	Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of Fluzoparib will be investigated.
NCT02575651 ↗	A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies	Completed	Jiangsu HengRui Medicine Co., Ltd.	Phase 1	Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of Fluzoparib will be investigated.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Fluzoparib

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Ovarian Cancer	10
Breast Cancer	3
Relapsed Ovarian Cancer	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Carcinoma, Ovarian Epithelial	14
Ovarian Neoplasms	14
Breast Neoplasms	12
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Fluzoparib

Trials by Country

Map
Table

Trials by Country
Location	Trials
China	51
Australia	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Fluzoparib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	7
Phase 2	25
Phase 1/Phase 2	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Not yet recruiting	23
Recruiting	19
Completed	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fluzoparib

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Jiangsu HengRui Medicine Co., Ltd.	28
Fudan University	7
Tianjin Medical University Cancer Institute and Hospital	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Other	33
Industry	32
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.